Opendata, web and dolomites
  1. home
  2. trasparenza
  3. open h2020
  4. hbmp-700

HbMP-700

The World's First Safe and Efficacious Human Blood Substitute: HbMP-700, a Haemoglobin based oxygen carrier, based on bovine blood.

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0
 Outcomes and results

 HbMP-700 project word cloud

Explore the words cloud of the HbMP-700 project. It provides you a very rough idea of what is the project "HbMP-700" about.

lyophilized    humans    conflicts    situation    human    victims    transfusions    25    transformed    trials    surgery    voluntary    conducting    compliant    feasibility    natural    manufacturing    demand    rbc    first    global    disasters    substitute    haematological    accidents    risk    technological    red    few    donors    care    introduction    afford    good    markets    subsequently    critical    months    proof    slaughterhouse    patented    bn    powder    infections    purification    unlimited    sufficient    donor    gcp    blood    representing    market    treat    business    stored    cell    shortages    infection    trial    35    malignancies    preclinical    mio    standard    excellent    types    extracted    total    severe    sme    bears    nearly    bovine    15nb    military    peak    700    contamination    patients    world    annually    economic    adding    supply    frequent    regulatory    safety    ery    laboratory    patient    weeks    85    hbmp    source    conduct    match    sales    develops    gmp    countries    compensate    leads    healthcare    clinical    cc    plan   

Project "HbMP-700" data sheet

The following table provides information about the project.

Coordinator		 CC-ERY GMBH 

Organization address
address: ROBERT-ROSSLE-STRASSE 10
city: BERLIN
postcode: 13125
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.
 Coordinator Country Germany [DE]
 Project website http://www.cc-ery.com
 Total cost 71˙429 €
 EC max contribution 50˙000 € (70%)
 Programme 1. H2020-EU.3.1.3. (Treating and managing disease)
 Code Call H2020-SMEINST-1-2016-2017
 Funding Scheme SME-1
 Starting year 2017
 Duration (year-month-day) from 2017-01-01   to  2017-04-30

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    CC-ERY GMBH DE (BERLIN) coordinator 50˙000.00

Map

 Project objective

CC-Ery GmbH develops HbMP-700, the world’s first substitute for human blood as a source for red blood cell (RBC) transfusions. 85 Mio. RBC transfusions are used p.a., representing a 10-15nb€ market. They are used to compensate for blood loss during surgery, treat patients with haematological malignancies, as well as victims of accidents, natural disasters, and military conflicts. The only source for RBC transfusions today are voluntary human blood donors. This leads to frequent supply shortages in the EU and other major healthcare markets. Donor blood must match patient blood. It can only be stored a few weeks, adding to the critical supply situation. Developing countries face a more severe situation as they cannot afford the standard of care of the developed world. In addition, human blood bears the risk of contamination with infections. HbMP-700 is extracted from bovine blood – a nearly unlimited, low cost supply source. It is transformed by a patented purification and manufacturing method to a lyophilized powder that is as effective as RBC transfusions from human blood, but bears no risk of infection, can be stored for months, and can be given to patients of all blood types. Bovine blood from one major EU slaughterhouse is sufficient to produce enough HbMP-700 to supply global demand for RBC transfusions. CC-Ery implemented the manufacturing method on a laboratory scale and is currently conducting preclinical trials, so far with excellent results. The objective of the SME Phase I project is to develop a business plan for the market introduction of HbMP-700. For this, a technological, regulatory, and economic feasibility analysis will be conducted. In Phase II, it is planned to build up a GMP (Good Manufacturing Practice) compliant manufacturing process and subsequently conduct a GCP (Good Clinical Practice) safety and proof of concept trial in humans. Total cost to market is estimated to be € 25-35 Mio. Peak sales are estimated to be more than € 1 bn. annually.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "HBMP-700" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "HBMP-700" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.1.3.)

MISTRAL (2020)

Microbiome-based stratification of individuals at risk of HIV-1 acquisition, chronic clinical complications,antimicrobial drug resistance,and unresponsiveness to therapeutic HIV-1 vaccination

Read More  

TT4CL (2019)

Clinical development of oral oleylphosphocholine as a new drug for the treatment of Old World Cutaneous Leishmaniasis

Read More  

PREFERABLE (2019)

Project on Exercise for Fatigue Eradication in Advanced Breast cancer to improve quality of life

Read More